

Global Uveitis Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

<https://marketpublishers.com/r/G84DD58CFFFEN.html>

Date: November 2017

Pages: 210

Price: US\$ 4,400.00 (Single User License)

ID: G84DD58CFFFEN

Abstracts

Global Uveitis Treatment Market

Uveitis is the term that describes a group of inflammatory diseases that affect the eye and produces swelling. Uveitis can reduce sight and may cause vision loss. Causes of uveitis include infections such as brucellosis, leptospirosis, syphilis, tuberculosis, autoimmune diseases such as sarcoidosis, Crohn's disease, multiple sclerosis, arthritis, ankylosing spondylitis, and psoriatic arthritis. In addition, uveitis is also caused by drugs such as rifabutin and moxifloxacin. Uveitis affects uvea, lens, retina, optic nerve, and vitreous. Uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis and pan-uveitis based on part of inflammation.

The main driver for the growth of uveitis market is the rise in prevalence and complications related to uveitis. In addition, increase in prevalence rates, market players betting heavily on research and development to develop new drugs, an introduction of biologics into the market, fast approval of the drugs are fuelling the market growth of uveitis treatment market. According to the Ocular Immunology and Uveitis Foundation, worldwide 2,359,242 people are estimated to have the disorder. Even there are significant advances in research and therapeutics, a prevalence of blindness secondary to uveitis has not been reduced in the past thirty years. However, few factors are restraining the growth of the market such as side effects of the drugs, eye irritation and lack of awareness about eye disorders in undeveloped regions, lack of sufficient healthcare infrastructure is hindering the uveitis treatment system market.

Uveitis treatment market segmented based on drug class, disease type, by cause and distribution channel

Based on drug class, uveitis treatment market is segmented into

Corticosteroids

Immunosuppressant

Monoclonal antibodies

Antibiotics

Antivirals

Antifungal

Analgesics

Based on disease type, uveitis treatment market is segmented into

Anterior Uveitis

Posterior Uveitis

Intermediate Uveitis

Panuveitis

Based on cause, uveitis treatment market is segmented into

Infectious Uveitis

Non-Infectious Uveitis

Based on distribution channel, uveitis treatment market is segmented into

Hospital Pharmacies

Retail Pharmacies

Others

Market players are developing novel molecules that can treat uveitis conditions in order to enhance their sales revenue. Companies are focusing on the development of the various drugs in the treatment of the uveitis. For instance, Aurinia Pharmaceuticals Inc. developing Luvenia, a calcineurin inhibitor for the treatment of noninfectious uveitis. Recently it has completed its phase-II clinical trials. Similarly, other pipeline drugs such as EMEA, DE-109, Gevokizumab, Peptide B27PD are being developed by different companies. Considering the aforementioned factors global uveitis treatment market is expected to grow at the significant rate during the forecast period.

Geographically uveitis treatment market segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is leading in uveitis treatment market due to various factors such as early approval of drugs compared to other regions, increased R&D investments by market players, and high prevalence of the uveitis is contributing growth of the market. In Europe region due to increased prevalence of diseases such as HIV, multiple sclerosis that are underlying causes of uveitis conditions. Japan, China, and India are expected to play important role in the revenue growth of the Asia-Pacific uveitis treatment market. China and India market growth is due to rapidly developing healthcare infrastructure, increased research and development expenditure and growing awareness about the eye-related diseases. However, manufacturing of eye preparations required aseptic conditions and the manufacturing plant should be GMP certified. Hence the cost related to these preparations is very high that has the direct implication on a cost of the drugs.

Some of the players in uveitis treatment market include AbbVie Inc. (U.S.), Eyegate Pharmaceuticals Inc. (US), Valeant Pharmaceuticals (Bausch + Lomb) (Canada), Novartis AG (Switzerland), Alimera Sciences Inc. (U.S.) and Santen Pharmaceutical Co. Ltd (Japan) to name a few.

In June 2016, U.S. Food and Drug Administration approved AbbVie's HUMIRA for the treatment of non-infectious intermediate, posterior and panuveitis

Report Outline:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL UVEITIS TREATMENT MARKET INTRODUCTION

2.1. Global Uveitis Treatment Market – Taxonomy

2.2. Global Uveitis Treatment Market –Definitions

2.2.1. Drug Class Type

2.2.2. Disease Type

2.2.3. Cause

2.2.4. Distribution Channel

3. GLOBAL UVEITIS TREATMENT MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Uveitis Treatment Market Dynamics – Factors Impact Analysis

3.6. Global Uveitis Treatment Market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Uveitis Treatment Market – Product Innovations

4. GLOBAL UVEITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL UVEITIS TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Corticosteroids

5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3. Market Opportunity Analysis

5.2. Immunosuppressant

5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.3. Market Opportunity Analysis

5.3. Monoclonal antibodies

5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.3.3. Market Opportunity Analysis

5.4. Antibiotics

5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.4.3. Market Opportunity Analysis

5.5. Antivirals

5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.5.3. Market Opportunity Analysis

5.6. Antifungal

5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.6.3. Market Opportunity Analysis

5.7. Analgesics

5.7.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.7.3. Market Opportunity Analysis

6. GLOBAL UVEITIS TREATMENT MARKET FORECAST, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Anterior Uveitis

6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.1.3. Market Opportunity Analysis

6.2. Posterior Uveitis

6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.2.3. Market Opportunity Analysis

6.3. Intermediate Uveitis

- 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 6.3.3. Market Opportunity Analysis

6.4. Panuveitis

- 6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 6.4.3. Market Opportunity Analysis

7. GLOBAL UVEITIS TREATMENT MARKET FORECAST, BY CAUSE, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Infectious Uveitis

- 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.1.3. Market Opportunity Analysis

7.2. Non-Infectious Uveitis

- 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 7.2.3. Market Opportunity Analysis

8. GLOBAL UVEITIS TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. Hospital Pharmacies

- 8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.1.3. Market Opportunity Analysis

8.2. Retail Pharmacies

- 8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.2.3. Market Opportunity Analysis

8.3. Others

- 8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 8.3.3. Market Opportunity Analysis

9. GLOBAL UVEITIS TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1. North America

- 9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 9.1.3. Market Opportunity Analysis

9.2. Europe

- 9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 9.2.3. Market Opportunity Analysis

9.3. Asia-Pacific

- 9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 9.3.3. Market Opportunity Analysis

9.4. Latin America

- 9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 9.4.3. Market Opportunity Analysis

9.5. Middle East and Africa

- 9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 9.5.3. Market Opportunity Analysis

9.6. Global Uveitis Treatment Market - Opportunity Analysis Index, By Drug Class Type, By Disease Type, Cause, Distribution Channel, and Region, 2017 – 2023

10. NORTH AMERICA UVEITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

- 10.1.1.1. Corticosteroids
- 10.1.1.2. Immunosuppressant
- 10.1.1.3. Monoclonal antibodies
- 10.1.1.4. Antibiotics
- 10.1.1.5. Antivirals
- 10.1.1.6. Antifungal
- 10.1.1.7. Analgesics

10.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

- 10.1.2.1. Anterior Uveitis
- 10.1.2.2. Posterior Uveitis

10.1.2.3. Intermediate Uveitis

10.1.2.4. Panuveitis

10.1.3. Cause Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Infectious Uveitis

10.1.3.2. Non Infectious Uveitis

10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Hospital Pharmacies

10.1.4.2. Retail Pharmacies

10.1.4.3. Others

10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

10.1.5.1. U.S.

10.1.5.2. Canada

10.1.6. North America Uveitis Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2017 – 2023

10.1.7. North America Uveitis Treatment Market Dynamics – Trends

11. EUROPE UVEITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1.1. Corticosteroids

11.1.1.2. Immunosuppressant

11.1.1.3. Monoclonal antibodies

11.1.1.4. Antibiotics

11.1.1.5. Antivirals

11.1.1.6. Antifungal

11.1.1.7. Analgesics

11.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. Anterior Uveitis

11.1.2.2. Posterior Uveitis

11.1.2.3. Intermediate Uveitis

11.1.2.4. Panuveitis

11.1.3. Cause Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Infectious Uveitis

11.1.3.2. Non Infectious Uveitis

11.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.4.1. Hospital Pharmacies

11.1.4.2. Retail Pharmacies

11.1.4.3. Others

11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.5.1. Germany

11.1.5.2. UK

11.1.5.3. France

11.1.5.4. Spain

11.1.5.5. Italy

11.1.5.6. Russia

11.1.5.7. Poland

11.1.5.8. Rest of Europe

11.1.6. Europe Uveitis Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2017 – 2023

11.1.7. Europe Uveitis Treatment Market Dynamics – Trends

12. ASIA-PACIFIC UVEITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1.1. Corticosteroids

12.1.1.2. Immunosuppressant

12.1.1.3. Monoclonal antibodies

12.1.1.4. Antibiotics

12.1.1.5. Antivirals

12.1.1.6. Antifungal

12.1.1.7. Analgesics

12.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Anterior Uveitis

12.1.2.2. Posterior Uveitis

12.1.2.3. Intermediate Uveitis

12.1.2.4. Panuveitis

12.1.3. Cause Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Infectious Uveitis

12.1.3.2. Non Infectious Uveitis

12.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Hospital Pharmacies

12.1.4.2. Retail Pharmacies

12.1.4.3. Others

12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.5.1. Japan

12.1.5.2. China

12.1.5.3. India

12.1.5.4. ASEAN

12.1.5.5. Australia & New Zealand

12.1.5.6. Rest of Asia-Pacific

12.1.6. Asia-Pacific Uveitis Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2017 – 2023

12.1.7. Europe Uveitis Treatment Market Dynamics – Trends

13. LATIN AMERICA UVEITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1.1. Corticosteroids

13.1.1.2. Immunosuppressant

13.1.1.3. Monoclonal antibodies

13.1.1.4. Antibiotics

13.1.1.5. Antivirals

13.1.1.6. Antifungal

13.1.1.7. Analgesics

13.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.2.1. Anterior Uveitis

13.1.2.2. Posterior Uveitis

13.1.2.3. Intermediate Uveitis

13.1.2.4. Panuveitis

13.1.3. Cause Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Infectious Uveitis

13.1.3.2. Non Infectious Uveitis

13.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.4.1. Hospital Pharmacies

13.1.4.2. Retail Pharmacies

13.1.4.3. Others

13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.5.1. Brazil

13.1.5.2. Mexico

13.1.5.3. Argentina

13.1.5.4. Venezuela

13.1.5.5. Rest of Latin America

13.1.6. Latin America Uveitis Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2017 – 2023

13.1.7. Latin America Uveitis Treatment Market Dynamics – Trends

14. MIDDLE EAST AND AFRICA UVEITIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

14.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.1.1. Corticosteroids

14.1.1.2. Immunosuppressant

14.1.1.3. Monoclonal antibodies

14.1.1.4. Antibiotics

14.1.1.5. Antivirals

14.1.1.6. Antifungal

14.1.1.7. Analgesics

14.1.2. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.2.1. Anterior Uveitis

14.1.2.2. Posterior Uveitis

14.1.2.3. Intermediate Uveitis

14.1.2.4. Panuveitis

14.1.3. Cause Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.3.1. Infectious Uveitis

14.1.3.2. Non Infectious Uveitis

14.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

14.1.4.1. Hospital Pharmacies

14.1.4.2. Retail Pharmacies

14.1.4.3. Others

14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

14.1.5.1. Gulf Cooperation Council (GCC) Countries

14.1.5.2. Israel

14.1.5.3. South Africa

14.1.5.4. Rest of MEA

14.1.6. MEA Uveitis Treatment Market - Opportunity Analysis Index, By Drug Class, Disease Type, Cause, Distribution Channel and Country, 2017 – 2023

14.1.7. MEA Uveitis Treatment Market Dynamics – Trends

15. COMPETITION LANDSCAPE

15.1. Strategic Dashboard of Top Market Players

15.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

15.2.1. AbbVie Inc. (U.S.)

15.2.2. Eyegate Pharmaceuticals Inc. (U.S.)

15.2.3. Valeant Pharmaceuticals (Bausch + Lomb) (Canada)

15.2.4. Novartis AG (Switzerland)

15.2.5. Alimera Sciences Inc. (U.S.)

15.2.6. Santen Pharmaceutical Co. Ltd (Japan)

16. RESEARCH METHODOLOGY

17. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Global Uveitis Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/G84DD58CFFFEN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G84DD58CFFFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

